Last reviewed · How we verify
Placebo to Benralizumab
Placebo to Benralizumab is a IL-5 receptor alpha subunit antagonist Biologic drug developed by AstraZeneca. It is currently in Phase 3 development for Severe asthma, Chronic obstructive pulmonary disease (COPD).
Benralizumab is a monoclonal antibody that targets the interleukin-5 receptor alpha subunit, leading to the depletion of eosinophils.
Benralizumab is a monoclonal antibody that targets the interleukin-5 receptor alpha subunit, leading to the depletion of eosinophils. Used for Severe asthma, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Placebo to Benralizumab |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | IL-5 receptor alpha subunit antagonist |
| Target | IL-5Rα |
| Modality | Biologic |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Benralizumab works by binding to the interleukin-5 receptor alpha subunit on the surface of eosinophils, which are a type of white blood cell involved in inflammation. This binding leads to the depletion of eosinophils, which are thought to contribute to the inflammation and damage seen in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
Approved indications
- Severe asthma
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Headache
- Nausea
- Injection site reaction
Key clinical trials
- Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment (PHASE3)
- Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics (PHASE4)
- A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA) (PHASE3)
- A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (PHASE3)
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (PHASE3)
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (PHASE3)
- Effect of Benralizumab in Atopic Dermatitis (PHASE2)
- Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Benralizumab CI brief — competitive landscape report
- Placebo to Benralizumab updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Placebo to Benralizumab
What is Placebo to Benralizumab?
How does Placebo to Benralizumab work?
What is Placebo to Benralizumab used for?
Who makes Placebo to Benralizumab?
What drug class is Placebo to Benralizumab in?
What development phase is Placebo to Benralizumab in?
What are the side effects of Placebo to Benralizumab?
What does Placebo to Benralizumab target?
Related
- Drug class: All IL-5 receptor alpha subunit antagonist drugs
- Target: All drugs targeting IL-5Rα
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Severe asthma
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD)
- Compare: Placebo to Benralizumab vs similar drugs
- Pricing: Placebo to Benralizumab cost, discount & access